Abstract: The present disclosure relates to a viral vector suitable for introducing a therapeutic agent, such as a peptide, protein or small RNA, into a host or otherwise treating a host. The vector may include an exogenous RNA segment with a hairpin-like structure or having two or more base-paired regions separated by one or more non-base-paired regions. The exogenous RNA segment may have a secondary structure, minimum free energy, average positional entropy or other attributes within specified ranges, or with values similar to one or more hairpin-like structures of a reference wild type virus. Optionally, the RNA vector may be derived from the reference wild type virus or a relative of the reference wild type virus. In some examples, the vector is capable of capable of systemic and phloem-limited movement and replication within a host plant. In some examples, the reference wild type virus is an umbravirus-like associated RNA.

Abstract: The present disclosure relates to a viral vector suitable for introducing a therapeutic agent, such as a peptide, protein or small RNA, into a host or otherwise treating a host. The vector may include an exogenous RNA segment with a hairpin-like structure or having two or more base-paired regions separated by one or more non-base-paired regions. The exogenous RNA segment may have a secondary structure, minimum free energy, average positional entropy or other attributes within specified ranges, or with values similar to one or more hairpin-like structures of a reference wild type virus. Optionally, the RNA vector may be derived from the reference wild type virus or a relative of the reference wild type virus. In some examples, the vector is capable of capable of systemic and phloem-limited movement and replication within a host plant. In some examples, the reference wild type virus is an umbravirus-like associated RNA.

Abstract: The specification describes an RNA vector. The vector may be derived from a plant virus or an umbravirus-like associated RNA such as Citrus yellow vein-associated virus (CYVaV). The vector contains a heterologous segment comprising a small interfering RNA (siRNA) that targets Xylella fastidiosa (Xf). In some examples, the heterologous segment may target the Xf PilG and/or TolC gene. The heterologous segment may be in the form of a hairpin structure inserted into a CYVaV-like molecule. A method of treating a plant against a disease caused by Xf includes introducing the vector into a plant before or after the plant is infected by Xf. The specification also describes a plant, or a portion of a plant, containing the vector and/or the heterologous segment. The plant may be a grapevine.

Abstract: The present disclosure relates to a single stranded RNA vector suitable for introducing a therapeutic agent, such as a peptide, a protein or a small RNA, into a host plant. The vector does not encode for any movement protein or coat protein, but is capable of capable of systemic and phloem-limited movement and replication within the host plant.

Abstract: The present disclosure relates to a single stranded RNA vector suitable for introducing a therapeutic agent, such as a peptide, a protein or a small RNA, into a host plant. The vector does not encode for any movement protein or coat protein, but is capable of capable of systemic and phloem-limited movement and replication within the host plant.

Abstract: The present disclosure relates to a single stranded RNA vector suitable for introducing a therapeutic agent, such as a peptide, a protein or a small RNA, into a host plant. The vector does not encode for any movement protein or coat protein, but is capable of capable of systemic and phloem-limited movement and replication within the host plant.